Physician profile
Amanda Wright
NPI 1306367149
$1,308.14
in general payments reported to CMS, 2019-2025
22 companies · $368 in 2025
The $368 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $227 · 2022: $289 · 2023: $187 · 2024: $237 · 2025: $368.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $792.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $791.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $260.89 | 2021-2025 | Airsupra, Breztri, Farxiga |
| Abbvie INC. | $183.97 | 2021-2025 | |
| Xeris Pharmaceuticals, INC. | $134.32 | 2022-2023 | Gvoke Hypopen |
| Novo Nordisk INC | $107.14 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Janssen Pharmaceuticals, INC | $88.48 | 2021-2022 | |
| Lilly USA, LLC | $78.43 | 2021-2025 | Zepbound, Mounjaro |
| Novartis Pharmaceuticals Corporation | $77.38 | 2022-2024 | |
| Dexcom, INC. | $57.65 | 2024-2025 | Dexcom G6 Transmitter |
| Exact Sciences Corporation | $49.79 | 2024-2025 | Cologuard Collection Kit |
| Abbott Laboratories | $44.43 | 2021-2023 | Freestyle Libre 3 |
| Vanda Pharmaceuticals INC. | $35.33 | 2025 | Fanapt, Hetlioz |
| Pfizer INC. | $27.25 | 2021-2025 | |
| Ironshore Pharmaceuticals INC. | $19.70 | 2021 | |
| Insulet Corporation | $19.52 | 2025 | Omnipod |
| Axsome Therapeutics, INC. | $18.33 | 2024 | Auvelity |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $16.93 | 2021 | |
| Seqirus USA INC | $16.56 | 2023 | Flucelvax Quadrivalent, Fluad Quadrivalent |
| Takeda Pharmaceuticals U.S.A., INC. | $15.41 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.87 | 2025 | Xifaxan |
| Biohaven Pharmaceutical Holding Company Ltd. | $14.63 | 2022 | |
| Astellas Pharma US INC | $14.01 | 2023 | Veozah |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.12 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Wright listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.